EQUITY ALERT: The Rosen Law Firm Files Securities Fraud Class Action Against Albany Molecular Research, Inc. - AMRI

NEW YORK, Nov. 12, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm announces that it has filed a class action lawsuit on behalf of purchasers of Albany Molecular Research, Inc. common stock AMRI between August 5, 2014 and November 5, 2014. The lawsuit seeks to recover damages for Albany Molecular investors under the federal securities laws.

To join the Albany Molecular class action, go to the website at http://www.rosenlegal.com/cases-428.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action. The suit is pending in U.S. District Court for the Eastern District of New York.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, Albany Molecular issued materially false and misleading statements about its business and financial prospects. On August 5, 2014, Albany Molecular Research announced its second quarter 2014 results and increased its 2014 adjusted EPS guidance to $0.87 - $0.92 to reflect the addition of OsoBio and the strengthening of its contract business. On November 5, 2014, Albany Molecular reported a loss of $8.6 million in its third quarter and lowered its 2014 adjusted EPS guidance to $0.67 and $0.73. It disclosed that a business interruption event at its OsoBio facility in late July, prior to its increased EPS estimates in August, contributed to a weak third quarter and the facility will not be back online until mid-November. On this adverse news, shares of Albany Molecular Research fell sharply during intraday trading on November 5, 2014, damaging investors.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2015. If you wish to join the litigation go to http://www.rosenlegal.com/cases-428.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.